Statistics from Altmetric.com
We thank Dr Bredemeier for his interest in our work.1 The need to measure duration as well as initial quality of response to a single cycle of rituximab has been recognised since the earliest trials using rituximab. Indeed, concomitant methotrexate was included in rituximab's license for rheumatoid arthritis because of improved duration of response, despite no difference in American College of Rheumatology (ACR) or European League Against Rheumatism (EULAR) response rates at 6 months.2 We therefore consider duration of response to be a meaningful outcome measure. We do not …
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.